Diabetes
| Cardiovascular
Diabetes
Cardiovascular
Substantial Cardiovascular Benefit from Icosapent Ethyl in Patients with Diabetes: REDUCE-IT DIABETES
book_2
Source:
ADA 2020 - Poster session
calendar_today
Published on Medfyle:
July 2020
headphones
5
min
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Key messages
- In REDUCE-IT, icosapent ethyl (IPE; 4 g/day) reduced CV risk vs. placebo in statin-treated patients with either DM plus risk factors or established CV disease.
- Patients with and without DM both showed substantial CV benefits, but patients with DM had 1.5-fold greater rates of the primary CV endpoint in the placebo group, and a 7% absolute risk reduction in first and a 12.7% reduction in total events (both p<0.001) with IPE.
- IPE 4 g/day provides robust CV benefits in statin-treated patients with DM, with large relative and absolute risk reductions in both first and total CV events.
Presenting Author
Read more
arrow_downward
Hide
arrow_upward
Deepak L Bhatt, MD, MPH, FESC
Brigham and Women’s Hospital Heart & Vascular Center
Harvard Medical School, Boston, MA USA
Disclosures
Read more
arrow_downward
Hide
arrow_upward
D.L.Bhatt: Research Support; Self; Abbott, Afimmune, Amarin Corporation, Amgen, AstraZeneca, Bayer Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Cardax, Chiesi USA, Inc., CSL Behring, Ferring Pharmaceuticals, Fractyl Laboratories, Inc., Idorsia, Ironwood Pharmaceuticals, Ischemix, Lexicon Pharmaceuticals, Inc., Lilly Diabetes, Medtronic, Pfizer Inc., PhaseBio Pharmaceuticals, Inc., PLx Pharma Inc., Regeneron Pharmaceuticals, Roche Pharma, Sanofi-Aventis, Synaptic.
